Subcutaneous Extended-Release Buprenorphine Use in Pregnancy
Background. Opioid use disorder (OUD) in pregnancy is managed by medication-assisted treatment. Sublingual buprenorphine is one option, but subcutaneous extended-release buprenorphine (Sublocade®) is an alternate form administered in monthly injections. Through an extensive literature search, we did...
Main Authors: | Craig V. Towers, Heather Deisher |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Case Reports in Obstetrics and Gynecology |
Online Access: | http://dx.doi.org/10.1155/2020/3127676 |
Similar Items
-
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
by: Melissa Velasquez, et al.
Published: (2019-10-01) -
Lipid bound extended release buprenorphine (high and low doses) and sustained release buprenorphine effectively attenuate post‐operative hypersensitivity in an incisional pain model in mice (Mus musculus)
by: Kaela Navarro, et al.
Published: (2021-06-01) -
Comparison of epidural morphine and buprenorphine for hindlimb orthopaedic surgery in dogs
by: Thomas Towers
Published: (2020-06-01) -
Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits
by: Raad Askar, et al.
Published: (2020-11-01) -
Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
by: Chappuy M, et al.
Published: (2021-06-01)